Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative tirzepatide for obesity in resectable gastrointestinal cancer
ACTRN12626000453381Phase 3Not yet recruiting
- Sponsor
- Monash Health
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Mounjaro with Placebo (2 arms). Primary endpoint: Total body weight loss. Planned start May 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12626000453381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000453381.